{
  "pmcid": "11075399",
  "abstract": "250-word version:\n\nTitle: Randomised Controlled Trial of an Implantable Arterial Access System for Chemotherapy and Peripheral Vascular Disease\n\nBackground: This study evaluated an implantable arterial access system for targeted chemotherapy delivery and isolated arterial-to-arterial extracorporeal perfusion in end-stage peripheral vascular disease.\n\nMethods: This single-arm pilot study included 10 patients with secondary colorectal cancer and 20 patients with critical limb ischemia. Eligibility criteria included histologically proven colorectal adenocarcinoma with inoperable hepatic metastases and critical limb ischemia with no option but amputation. The primary outcome for chemotherapy was partial response or stable disease over 11.2 months. For peripheral vascular disease, the primary outcome was avoidance of major amputation over 22 months. The trial was registered (ACTRN12611001273976) and approved by the institutionâ€™s Human Ethics Committee.\n\nResults: In the chemotherapy group, six out of ten patients achieved partial response or stable disease. In the peripheral vascular disease group, 40% avoided amputation, and 20% had a delay of 4 months. Adverse events included a 4% infection rate and one minor thromboembolic event.\n\nInterpretation: The access system allows repeatable multi-catheter arterial access for chemotherapy, addressing issues of concentration and microvascular control. It supports extracorporeal arterial-to-arterial access, generating flows greater than 1 L/min. The device logistics compare favorably with arteriovenous and venovenous access systems.",
  "word_count": 207
}